Welcome to our dedicated page for Rezolute news (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.
Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute (Nasdaq: RZLT) announced that its CEO, Nevan Charles Elam, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 1:00 p.m. ET in New York City. The event will feature a live webcast available on Rezolute's investor relations website, which will be archived for 90 days. Additionally, the management team will engage in one-on-one meetings with investors throughout the conference.
Rezolute announced positive topline results from its Phase 2 study of RZ402 in Diabetic Macular Edema (DME) patients. The study met primary endpoints, showing a significant reduction in central subfield thickness (CST) and a good safety profile. This is the first oral therapy to demonstrate such effects, highlighting potential for early disease intervention. The study involved 94 participants and evaluated three dosages over 12 weeks. Results indicated a significant improvement in CST, especially at the 200 mg dose, with no severe adverse effects related to the drug. A virtual investor event will be held today at 5:30 pm ET to discuss these findings.
Rezolute, a clinical-stage biopharmaceutical company, reported its third quarter financial results for fiscal 2024, ending March 31, 2024. The company announced the initiation of patient enrollment in the global Phase 3 clinical study of RZ358 for congenital hyperinsulinism (cHI), with topline results expected mid-2025. Rezolute also completed an in-vivo toxicology study in Norway rats, showing no liver abnormalities at the highest dose tested. Ongoing interactions with the FDA aim to resolve partial clinical holds for RZ358.
In other developments, Rezolute completed patient dosing in a Phase 2 study of RZ402 for diabetic macular edema, with topline results expected in May 2024. Financially, the company reported cash and equivalents of $81.6 million, a decrease from $118.4 million as of June 30, 2023. Research and development expenses were $12.4 million, and general and administrative expenses rose to $3.8 million. Net loss stood at $17.1 million, compared to $15.7 million a year ago.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.